Evidence map›Paper›PMID 31828320›Full record

ArticleThe Journal of infectious diseases2020

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.

Dominique Costagliola, Valérie Potard, Sylvie Lang, Nathalie de Castro, Laurent Cotte, Xavier Duval, Claudine Duvivier, Sophie Grabar, Murielle Mary-Krause, Marialuisa Partisani and 8 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Dominique CostagliolaSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Valérie PotardSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Sylvie LangSorbonne Université, APHP, Hôpital Saint-Antoine, Hôpitaux de l'Est Parisien, Service de Cardiologie, Paris, France.
Nathalie de CastroAPHP, Hôpital Saint-Louis, Paris, France.
Laurent CotteDepartment of infectious Diseases, Hospices Civils de Lyon, and INSERM U1052, Lyon, France.
Xavier DuvalAPHP, Hopital Bichat, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Claudine DuvivierInstitut Pasteur, Centre Médical, Centre d'Infectiologie Necker Pasteur, APHP, Hôpital Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, CNRS UMR8104, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Institut Cochin, Paris, France.
Sophie GrabarSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Murielle Mary-KrauseSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Marialuisa PartisaniHôpitaux Universitaires de Strasbourg, Strasbourg, France.
Sylvie Ronot-BregigeonAP-HM Hôpital Sainte Marguerite, Service Immuno-Hématologie Clinique, Marseille, France.
Anne SimonAPHP, Hôpital Pitié-Salpêtrière, Paris, France.
Pierre TattevinCHU Rennes, Hôpital Pontchaillou, Maladies Infectieuses et Réanimation Médicale, Rennes, France.
Laurence WeissAPHP, Hôpital Européen Georges Pompidou, Université Paris-Descartes Sorbonne Paris Cité, Paris, France.
David ZucmanHôpital Foch, Suresnes, France.
Christine KatlamaSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
François RaffiDepartment of Infectious Diseases, University Hospital of Nantes and CIC 1413, INSERM, Nantes, France.
Franck BoccaraSorbonne Université, APHP, Hôpital Saint-Antoine, Hôpitaux de l'Est Parisien, Service de Cardiologie, Paris, France.
Inserm · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Foch · FRHôpital Necker-Enfants Malades · FRHôpital Pontchaillou · FRHôpital Sainte-Marguerite · FRHôpitaux Universitaires de Strasbourg · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an increased risk of cardiovascular diseases in people with human immunodeficiency virus who were exposed to darunavir (DRV) but not to atazanavir (ATV). Our objective was to evaluate associations between ATV or DRV exposures and the risk of myocardial infarction (MI) in a nested case-control study within ANRS-CO4 French Hospital Database on HIV (FHDH).

methodsCases were individuals who had a first validated MI between 2006 and 2012. Up to 5 controls were selected at random with replacement among individuals with no history of MI, followed at the time of MI diagnosis, and matched for age and sex. Conditional logistic regression models were used to adjust for potential confounders (MI risk factors and HIV-related parameters) and for cumulative exposure to each antiretroviral drug (ARV).

resultsOverall, 408 MI cases and 1250 controls were included: 109 (27%) cases and 288 (23%) controls had been exposed to ATV, and 41 (10%) cases and 107 (9%) controls had been exposed to DRV. There was no significant association between exposure to ATV (adjusted odds ratio [OR] = 1.54; 95% confidence interval [CI], .87-2.73) or DRV (adjusted OR = 0.51; 95% CI, .11-2.32) and the risk of MI.

conclusionsIn FHDH, exposures to ATV or to DRV were not significantly associated with the risk of MI, adjusting for complete ARV history, contrary to the analysis in DAD.

Indexed as

HIV-1AdultAtazanavir SulfateCase-Control StudiesCohort StudiesDarunavirDatabases, FactualFemaleHIV InfectionsHIV Protease InhibitorsHumansMaleMiddle AgedMyocardial InfarctionRisk FactorsTreatment OutcomeAtazanavir SulfateDarunavirHIV Protease Inhibitorsantiretroviral drugsatazanavirdarunavirHIVmyocardial infarction

Identifiers

PMID31828320
OpenAlexW2995265141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.